Penfigoide bulloso asociado a vildagliptina en adulto mayor con diabetes mellitus. Primer caso en Perú
DOI:
https://doi.org/10.17843/rpmesp.2025.421.13871Palabras clave:
Penfigoide Ampolloso, Inhibidores de la Dipeptidil-Peptidasa IV, Vildagliptina, Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos, Informes de CasosResumen
La vildagliptina, un inhibidor de la dipeptidil peptidasa-4 (DPP-4i) utilizado en el tratamiento de la diabetes mellitus tipo 2 (DM2), se destaca por su seguridad en adultos mayores. Sin embargo, se asocia con reacciones adversas, como el penfigoide ampollar (PA), aunque hasta el momento no se han documentado casos en Perú. Se reporta un paciente varón de 76 años con hipertensión y DM2 que inició tratamiento con vildagliptina y metformina. Después de un mes, presentó lesiones cutáneas pruriginosas, ampollosas y ulceradas, conduciendo al diagnóstico de PA. El PA, asociado a DPP-4i, afecta principalmente a adultos mayores, manifestándose en promedio unos 9 meses después del inicio del tratamiento. Su diagnóstico se basa en criterios clínicos, histopatología e inmunofluorescencia. El tratamiento incluye la suspensión del fármaco y el uso de corticoides. La vildagliptina, aunque segura y efectiva, puede provocar PA, que
requiere un diagnóstico y tratamiento oportuno debido a su alta mortalidad.
Descargas
Referencias
Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019. doi: 10.1210/er.2014-1035.
Hayashi T, Murayama H, Shinfuku Y, Taniguchi T, Tsumiyama I, Oyama N. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin. Expert Opin Pharmacother. 2020 Jan;21(1):121–30. doi: 10.1080/14656566.2019.
Mathieu C, Kozlovski P, Paldánius PM, Foley JE, Modgill V, Evans M, et al. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017;13(2):68–72. doi: 10.17925/EE.2017.13.02.68.
Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021;37(3):e3391. doi: 10.1002/dmrr.3391.
Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020;69(3):504–7. doi: 10.1007/s12020-020-02272-x.
Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol. 2020;61(1):e15–21. doi: 10.1111/ajd.13100.
Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. J Transl Med. 2021;19:520. doi: 10.1186/s12967-021-03192-8.
Leisti P, Pankakoski A, Jokelainen J, Huilaja L, Panelius J, Tasanen K, et al. Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid. Acta Derm Venereol. 2024;104:40645. doi: 10.2340/actadv.v104.40645.
Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care. 2018;41(9):e130–2. doi: 10.2337/dc18-0210.
Carnovale C, Mazhar F, Arzenton E, Moretti U, Pozzi M, Mosini G, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®. Expert Opin Drug Saf. 2019;18(11):1099–108. doi: 10.1080/14740338.2019.1668373.
Béné J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175(2):296–301. doi: 10.1111/bjd.14601.
Molina-Guarneros JA, Sainz-Gil M, Sanz-Fadrique R, García P, Rodríguez-Jiménez P, Navarro-García E, et al. Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases. Int J Clin Pharm. 2020;42(2):713–20. doi: 10.1007/s11096-020-01003-6.
Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. Am J Clin Dermatol. 2021;22(6):891–900. doi: 10.1007/s40257-021-00625-4.
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Front Immunol. 2019;10:1238. doi: 10.3389/fimmu.2019.01238.
Sun L, Wang C, Wu C, Zhou Y, Wang C. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid. Ann Pharmacother. 2022;56(2):205–12. doi: 10.1177/10600280211022722.
Kridin K, Shihade W, Bergman R. Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. Acta Derm Venereol. 2019;99(1):72–7. doi: 10.2340/00015555-2930.
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bullous pemphigoid. Autoimmun Rev. 2017 May;16(5):445–55. doi: 10.1016/j.autrev.2017.03.010.
Mai Y, Nishie W, Izumi K, Shimizu H. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180. Front Immunol. 2019 May 29;10:1224. doi: 10.3389/fimmu.2019.01224.
Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes. 2021;12(9):1426–41. doi: 10.4239/wjd.v12.i9.1426.
Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006;116(5):1159–66. doi: 10.1172/JCI28547.
Okazaki A, Miyagawa S, Yamashina Y, Kitamura W, Shirai T. Polymorphisms of HLA-DR and -DQ Genes in Japanese Patients with Bullous Pemphigoid. J Dermatol. 2000;27(3):149–56. doi: 10.1111/j.1346-8138.2000.tb02141.x.
Hirose M, Schilf P, Benoit S, Eming R, Gläser R, Homey B, et al. Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German
population. Exp Dermatol. 2015;24(9):715–7. doi: 10.1111/exd.12732.
Rychlik-Sych M, Barańska M, Wojtczak A, Skrętkowicz J, Żebrowska A, Waszczykowska E. The impact of the CYP2D6 gene polymorphism on the risk of pemphigoid. Int J Dermatol. 2015;54(12):1396–401. doi: 10.1111/ijd.12967.
Weisenseel P, Martin S, Partscht K, Messer G, Prinz JC. Relevance of the low-affinity type of the Fcγ-receptor IIIa-polymorphism in bullous pemphigoid. Arch Dermatol Res. 2007;299(3):163–4. doi: 10.1007/s00403-007-0755-8.
Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. JDDG J Dtsch Dermatol Ges. 2015;13(8):833–44. doi: 10.1111/ddg.12606.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Juan Eduardo Quiroz-Aldave, Janet Ángeles-Zavaleta, María del Carmen Durand-Vásquez, José Paz-Ibarra, Janneth Y. Quispe-Meza, Marcio Concepción-Zavaleta; Cristian D. Armas; Luis Concepción-Urteaga
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
